EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France
Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.548
https://www.valueinhealthjournal.com/article/S1098-3015(22)02752-8/fulltext
Title :
EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02752-8&doi=10.1016/j.jval.2022.09.548
First page :
Section Title :
Open access? :
No
Section Order :
10079